Form 8-K - Current report:
SEC Accession No. 0001564590-22-019267
Filing Date
2022-05-10
Accepted
2022-05-10 16:06:34
Documents
14
Period of Report
2022-05-10
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K arwr-8k_20220510.htm   iXBRL 8-K 37190
2 EX-99.1 arwr-ex991_6.htm EX-99.1 236106
3 GRAPHIC ghvnqo5ppwcq000001.jpg GRAPHIC 49974
  Complete submission text file 0001564590-22-019267.txt   483219

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA arwr-20220510.xsd EX-101.SCH 5625
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE arwr-20220510_lab.xml EX-101.LAB 19320
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE arwr-20220510_pre.xml EX-101.PRE 11513
8 EXTRACTED XBRL INSTANCE DOCUMENT arwr-8k_20220510_htm.xml XML 3561
Mailing Address 177 E COLORADO BLVD SUITE 700 PASADENA CA 91105
Business Address 177 E COLORADO BLVD SUITE 700 PASADENA CA 91105 626-696-4702
ARROWHEAD PHARMACEUTICALS, INC. (Filer) CIK: 0000879407 (see all company filings)

EIN.: 460408024 | State of Incorp.: DE | Fiscal Year End: 0930
Type: 8-K | Act: 34 | File No.: 001-38042 | Film No.: 22909541
SIC: 2834 Pharmaceutical Preparations